Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Five Dock, Australia Clinical Trials

A listing of Five Dock, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (21) clinical trials

Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS

Multicenter, multiple dose study to examine the effect of H.P. Acthar Gel (repository corticotropin injection) in adult subjects with idiopathic focal segmental glomerulosclerosis (FSGS) who have failed to achieve remission with, or who are intolerant of, 1 or more previous immunosuppressive therapies.

Phase

2.09 miles

Learn More »

Plasma-Lyte 148 versUs Saline Study

Fluid resuscitation is a fundamental component of the management of acutely and critically ill patients and the choice of fluid is a longstanding issue of debate. Worldwide, 0.9% saline has traditionally been the most widely used resuscitation fluid, however its use is increasingly challenged by emerging evidence that suggests its ...

Phase

2.75 miles

Learn More »

Randomised Evaluation of Sodium Dialysate Levels on Vascular Events

RESOLVE is a pragmatic, cluster-randomised, open-label trial designed to evaluate in real-world conditions the comparative effectiveness of two default dialysate sodium concentrations. Dialysis sites will be randomised in a 1:1 ratio to a default dialysate sodium concentration of 137mmol/l or 140mmol/l. 'Default' is defined as the use of the allocated ...

Phase

2.75 miles

Learn More »

Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy

Data from a previous single arm study (RESPITE) indicate that transition from PDE5i to riociguat may be feasible, safe and beneficial in patients not adequately responding to PDE5i. REPLACE is a randomized controlled study to confirm the potential clinical benefit of transition from PDE5i to riociguat. Satisfactory clinical response in ...

Phase

3.25 miles

Learn More »

Randomized Embedded Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Patients with pneumonia who are being treated in an ICU will receive many different treatments, as many as 20 or 30, that act together to treat both the infection and its effects on the body. When treating a patient, doctors choose from many different treatments, most of which are known ...

Phase

3.25 miles

Learn More »

Study of OCA Evaluating Pharmacokinetics and Safety in Patients With PBC and Hepatic Impairment

This Phase 4, randomized, double-blind, placebo-controlled study will evaluate the PK and safety of OCA treatment in patients with primary biliary cholangitis (PBC) and moderate to severe hepatic impairment over a 48 week treatment period. Patients who have completed their 48-week double blind treatment period will continue double-blind treatment until ...

Phase

3.25 miles

Learn More »

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis

This Phase 4, double-blind, randomized, placebo-controlled, multicenter study is being undertaken at up to 170 sites internationally to evaluate the effect of OCA on clinical outcomes in 428 subjects with PBC. The study will include a screening period of up to 8 weeks, requiring two clinic visits. Eligible participants will ...

Phase

3.41 miles

Learn More »

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to ...

Phase

3.41 miles

Learn More »

A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

The FAME 3 trial is a multicenter, international, randomized, controlled noninferiority trial. All patients with multivessel CAD (not involving the left main) will be screened by the site's Heart Team (including but not limited to an interventional cardiologist, cardiac surgeon and research coordinator). If all agree that the patient can ...

Phase

4.64 miles

Learn More »

Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis

Name of investigational treatment: Influenza vaccine (Vaxigrip, Sanofi Pasteur MSD). Title of study: Influenza vaccination After Myocardial Infarction (IAMI trial). Study centers: Up to 35 centers in Sweden, Denmark, Norway, Scotland, Czech Rebublic and Latvia. Planned study period: 2016 - 2019 from October 1 to March 1 (influenza season). Long-term ...

Phase

4.64 miles

Learn More »